PTC制药
PTCT
59.24
-1.75
-2.87%
PTC制药
US · PTCT
#2071 按市值排名
上市于 1970
59.24
-1.75
-2.87%
实时 - 追踪5344个代码 - 心跳于518秒前
· 2026-10-16 19:30
最新新闻
-
评级变动
BofA Securities Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Announces Target Price $95\u5e02\u573a\u8d44\u8baf · 2026/7/15
-
评级变动
Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $130\u5e02\u573a\u8d44\u8baf · 2026/7/16
-
评级变动
Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $130\u5e02\u573a\u8d44\u8baf · 2026/8/13
-
评级变动
Goldman Sachs Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Raises Target Price to $70\u5e02\u573a\u8d44\u8baf · 2026/7/31
-
评级变动
Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $109\u5e02\u573a\u8d44\u8baf · 2026/8/13
-
Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $109\u5e02\u573a\u8d44\u8baf · 2026/9/2
-
Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $137\u5e02\u573a\u8d44\u8baf · 2026/9/22
-
评级变动
RBC Capital Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Raises Target Price to $85\u5e02\u573a\u8d44\u8baf · 2026/7/27
-
评级变动
Morgan Stanley Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Cuts Target Price to $93\u5e02\u573a\u8d44\u8baf · 2026/7/23
-
PTC Therapeutics, Inc.: To Assume Certain Specified Liabilities of Sangamo PTCTDow Jones · 2026/8/29
-
评级变动
A Quick Look at Today's Ratings for PTC Therapeutics(PTCT.US), With a Forecast Between $90 to $106\u5e02\u573a\u8d44\u8baf · 2026/7/31
-
评级变动
BofA Securities Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $96\u5e02\u573a\u8d44\u8baf · 2026/8/13
-
评级变动
Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $122\u5e02\u573a\u8d44\u8baf · 2026/8/14
-
评级变动
Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $106\u5e02\u573a\u8d44\u8baf · 2026/7/31
-
TD Cowen Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $90\u5e02\u573a\u8d44\u8baf · 2026/8/31
-
评级变动
Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $120\u5e02\u573a\u8d44\u8baf · 2026/8/4
-
PTC Therapeutics, Inc.: Upfront Payment of $111 Million, Plus Up to an Additional $100 Million in Contingent Milestone Payments PTCTDow Jones · 2026/8/29
-
评级变动
Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $93\u5e02\u573a\u8d44\u8baf · 2026/7/21
-
评级变动
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), Doximity (DOCS) and PTC Therapeutics (PTCT)TipRanks · 2026/7/21
-
评级变动
Morgan Stanley Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $104\u5e02\u573a\u8d44\u8baf · 2026/7/31
新闻标题为自动聚合内容,未经我们团队独立核实或编辑。
报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
PTC制药 讨论区 0 条评论